BioProtein Technologies launches TRM a subsidiary dedicated to the
production of genetically modified rabbit models
Transgenic Rabbit Models leans on twenty years of expertise in lagomorphs transgenesis, some of the
most relevant animal models for studying complex diseases.
Jouy-en-Josas, France – February 15, 2010 – BioProtein Technologies the biotechnology company
committed to the production of therapeutic proteins in the milk of transgenic rabbits, is proud to
announce the launch of its subsidiary: Transgenic Rabbit Models (TRM), dedicated to the development
of genetically modified research models with a high value-added for the biopharmaceutical industry
and academic research.
TRM provides genetically modified rabbit models for biomedical research, a species relatively underexploited
until now compared to mice and rats. With the improvement of handling techniques, gene
replacement and the development of specific proprietary methods for rabbits (knock-down, knock-out
or knock-in), Transgenic Rabbit Models can now provide biotechnology and pharmaceutical
companies or academic laboratories, with fully integrated services intended for the design and
production of transgenic rabbit models for biomedical research.
Alexandre Fouassier, CEO of Transgenic Rabbit Models, declared: « Contrary to common beliefs, rabbits
are not rodents. They belong to the order of lagomorphs and are phylogenetically closer to primates
than rodents or ruminants. It is therefore an attractive animal for producing human glycoproteins and
recombinant vaccines, our ongoing activity with BioProtein. The particularities of the rabbit and the
development of specific genetic engineering tools makes it one of the most promising animal model to
open new pathways of research on complex diseases like diabetes, obesity, atherosclerosis, heart
diseases, major ophthalmic diseases or various cancers. With a short-time gestation and early sexual
maturity, we are able to generate lines of transgenic animals in very short time. We are convinced that
this market will register a very strong growth in the years to come. TRM, which has already a strong
expertise in transgenesis and breeding, intends to become the undisputed leader in this field of
Traditional transgenic models (rats, mice) are widely used by the scientific community for biomedical
research. These models are however imperfect in a number of situations. The development of
alternative and complementary transgenic models and especially in rabbits, brings a significant added
value when studying complex human diseases. Some more effective therapeutic solutions can be
designed using lagomorph models.
Transgenic Rabbit Models (TRM) is a biotechnology dedicated to the development of specific and
standardized genetically modified animal models for the needs of the biopharmaceutical industry and
academic research. TRM gathers over twenty years of expertise in transgenic rabbits acquired by its
parent company, BioProtein Technologies SA, a specialist in the production of recombinant proteins in
the milk of transgenic animals.
TRM intends on meeting the needs of its customers by providing high value-added genetically modified
models designed through a proprietary technology platform and exclusive know-how. The rabbit is a
relevant animal model for studying various human diseases, especially in areas such as atherosclerosis,
diabetes, ophthalmology, myopathy hypertrophic obesity, hemostasis, respiratory diseases, AIDS or
various forms of cancer.
For more information please visit: www.transgenic-rabbit-models.com